Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Inclusion: * Patients must have histologic diagnosis of adenocarcinoma of the prostate with progression following hormonal therapy and antiandrogen withdrawal. * Patients must have minimal disease (defined as bone metastasis or visceral disease with no impairment of organ function or pain severe enough to require narcotics for control). * Adequate bone marrow and renal function * ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 (a measure of general well being where 1 represents asymptomatic and 5 represents death) * Life expectancy of at least 16 weeks * Must have completed radiation more than 4 weeks prior to registration and must have a rising PSA (Prostate Specific Antigen) and lesion outside of the radiation field Exclusion: * Patients with an elevated PSA as the only evidence of disease * Clinical evidence of spinal cord compression * History of prior malignancy within the past 5 years (with the exception of in situ carcinoma of any site or nonmelanoma skin cancer)